
By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
African Forests Have Become a Source of Carbon Emissions - 2
The most effective method to Guarantee Simple Availability in Seniors' SUVs - 3
Artemis 2 breaks humanity's all-time distance record during historic loop around the moon (video) - 4
Cyprus urges hotels to open up, pours funding into tourism - 5
The Most recent Microsoft Surface Genius PC: Ideal for Very good quality Planning and Gaming Needs
Gartex Texprocess India to showcase innovations across textile ecosystem
The 10 Most Famous Style Minutes on Honorary pathway
A throat bone settles it - Nanotyrannus was not a juvenile T. rex
6 Web-based Course Stages for Successful Learning and Educating
'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
Man threatens attack on German high-speed train, injures several
New dietary guidelines recommend more dairy, meat and fats: What to know
Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
'Everyone in this prison has had family killed or shot'













